Hikma Pharmaceuticals (STU:H5P) Construction In Progress: €407 Mil (As of Dec. 2025)


STU:H5P Hikma Pharmaceuticals PLC STU:H5P
81 GF Score
Price €17.75
GF Value €24.62
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Construction In Progress?

Hikma Pharmaceuticals STU:H5P -0.06% 81 Construction In Progress is €407 Mil as of Dec. 2025. GuruFocus rates STU:H5P with a GF Score™ of 81/100 and a GF Value™ of €24.62 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Hikma Pharmaceuticals's quarterly construction in progress declined from Dec. 2024 (€391 Mil) to Jun. 2025 (€0 Mil) but then increased from Jun. 2025 (€0 Mil) to Dec. 2025 (€407 Mil).

Hikma Pharmaceuticals's annual construction in progress increased from Dec. 2023 (€249 Mil) to Dec. 2024 (€391 Mil) and increased from Dec. 2024 (€391 Mil) to Dec. 2025 (€407 Mil).

Hikma Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Construction In Progress Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 239.84 247.33 249.42 390.60 407.36

Hikma Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 249.42 0.00 390.60 0.00 407.36
STU:H5P
81GF Score
Hikma Pharmaceuticals PLC STU:H5P
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €407 Mil mean?
Hikma Pharmaceuticals (STU:H5P) has a Construction In Progress of €407 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Construction In Progress too high?
Hikma Pharmaceuticals' current Construction In Progress is €407 Mil. Overall, Hikma Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Construction In Progress compare to ZTS and UTHR?
Hikma Pharmaceuticals' Construction In Progress of €407 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Construction In Progress is €407 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (STU:H5P) is currently considered Modestly Undervalued. The stock's GF Value™ is €24.62, compared to a current price of €17.75 — trading 27.9% below its estimated fair value. The current Construction In Progress is €407 Mil. Hikma Pharmaceuticals' overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Hikma Pharmaceuticals (STU:H5P), the current Construction In Progress is €407 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (STU:H5P) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of €17.75 is trading 27.9% below its estimated GF Value™ of €24.62. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:H5P:

  • Construction In Progress: €407 Mil
  • GF Value™: €24.62 vs. price of €17.75 (27.9% below fair value)
  • GF Score™: 81/100 with 5 warning signs

No single metric tells the full story. See the STU:H5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
81GF Score

Get the complete analysis for STU:H5P

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.75
Price
€24.62
GF Value